Researchers and pharma companies partner to investigate new schizophrenia treatment
pharmafile | January 21, 2021 | News story | | Biogen, Boehringer Ingelheim
The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a new drug target for the treatment of schizophrenia.
The project is the first to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high-value drug discovery projects in this area of unmet patient need.
The team of academic researchers will use a newly designed technical approach to assess which proteins are selectively produced by the kalirin gene in the human brain, and how this differs from other human tissues. Once this is understood, the team may be able to identify the proteins that represent the most promising drug targets for treating schizophrenia, how they affect the function of cells, and begin to develop drugs to alter their function.
Liz Tunbridge, Associate Professor at the University of Oxford, and lead investigator for the study, commented: “We desperately need new treatments for schizophrenia because current drugs can cause side effects, do not work for everyone, and do not improve all the symptoms. However, it has been difficult to improve this situation because of our limited understanding of the changes in the brain that underlie schizophrenia.
“This exciting collaboration will enable us to start the long journey from genetic research to the development of new drugs. Ultimately, we hope that our research will one day lead to new medicines that improve the lives of people with schizophrenia.”
Dr Hugh Marston, Head of Department CNS Diseases Research at Boehringer Ingelheim, also commented: “Schizophrenia is a serious mental health condition that alters a person’s perception of reality, impacts how they think, feel, and behave. Current treatment options leave significant room for improvement through the development of new therapeutics.
“We recognize the importance of finding new solutions for people living with neuropsychiatric disorders with our innovative CNS research program as a key focus area at Boehringer Ingelheim. As this programme focuses on improving our understanding of the mechanisms that underly these complex disorders, we are pleased to be part of this first research project of the Psychiatry Consortium. We hope a successful completion will make a real impact on the development of innovative treatment options.”
Darcy Jimenez
Related Content
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …
Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment
Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment …
Eisai shares new data for Leqembi for Alzheimer’s treatment
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL …
